Long acting teriparatide - Shenzhen Salubris Pharmaceuticals
Alternative Names: SAL-056Latest Information Update: 20 Sep 2023
At a glance
- Originator Shenzhen Salubris Pharmaceuticals
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoporosis
Most Recent Events
- 19 Jul 2023 Phase-III clinical trials in Osteoporosis (SC, Controlled release) (before July 2023) (Shenzhen Salubris Pharmaceuticals Pipeline, July 2023)